Log In
Print
BCIQ
Print
Print this Print this
 

G305, ID-G305

  Manage Alerts
Collapse Summary General Information
Company Immune Design Corp.
DescriptionImmunotherapy consisting of recombinant cancer/testis antigen 1B (CTAG1B; NY-ESO-1) antigen and the GLA-SE adjuvant
Molecular Target Cancer/testis antigen 1B (CTAG1B) (NY-ESO-1)
Mechanism of ActionVaccine; Immunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat unresectable, relapsed or metastatic cancer expressing NY-ESO-1
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today